Charles Schwab Investment Management Inc. Purchases 41,558 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Charles Schwab Investment Management Inc. grew its position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 33.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 166,635 shares of the company’s stock after buying an additional 41,558 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.39% of Kyverna Therapeutics worth $815,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Creative Planning bought a new position in Kyverna Therapeutics during the third quarter worth about $54,000. Federated Hermes Inc. bought a new position in shares of Kyverna Therapeutics during the second quarter worth approximately $120,000. Rhumbline Advisers acquired a new stake in shares of Kyverna Therapeutics in the second quarter valued at approximately $150,000. Teachers Retirement System of The State of Kentucky boosted its stake in shares of Kyverna Therapeutics by 69.7% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 21,410 shares of the company’s stock valued at $161,000 after buying an additional 8,796 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ grew its position in Kyverna Therapeutics by 55.8% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company’s stock worth $196,000 after buying an additional 9,385 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Performance

KYTX stock opened at $3.79 on Thursday. The company’s fifty day simple moving average is $4.97 and its 200 day simple moving average is $6.98. Kyverna Therapeutics, Inc. has a 12-month low of $3.77 and a 12-month high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. Sell-side analysts expect that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on KYTX. HC Wainwright dropped their price objective on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Rodman & Renshaw began coverage on Kyverna Therapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $16.00 price target for the company. Wells Fargo & Company decreased their target price on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. UBS Group initiated coverage on shares of Kyverna Therapeutics in a report on Thursday, October 10th. They set a “buy” rating and a $13.00 price target for the company. Finally, RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.71.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.